Kir4.2 potassium channel as a novel drug target for Parkinson’s disease inflammation

Overview

This research program positions the Kir4.2 (KCNJ15) potassium channel as a novel biological target for the inflammatory component of Parkinson’s disease (PD). The team identified a loss-of-function genetic variant, KCNJ15p.R28C, that fully segregates with PD across four generations of one affected family and has appeared in two additional independent PD families. Functional studies show the variant reduces Kir4.2 protein expression and K+ currents, and KCNJ15 knockout mice display both motor and non-motor deficits. Because Kir4.2 is predominantly expressed in neutrophils in peripheral blood, the program pursues two complementary hypotheses: that Kir4.2 drives neutrophil-mediated systemic inflammation in PD, and that it contributes to microglia-mediated neuroinflammation. The work combines patient-derived iPSCs, 3D dopaminergic neuron and microglia differentiation, knockout mouse models, and proteomics to validate the channel as a druggable target.

Technical specifications

Genetic and cellular models:

• Four iPSC lines carrying KCNJ15p.R28C sourced from affected family members, with mutation-corrected wild-type controls in development
• KCNJ15 knockout mouse model evaluated through DigiGait and additional behavioral assays
• 3D culture differentiation of iPSCs into dopaminergic neurons and microglia

Neutrophil functional assays (planned):

• Phagocytosis, chemotaxis, ROS/NOS production, catecholamine and cytokine release, degranulation, apoptosis, and NETosis using Histopaque-isolated neutrophils from knockout and wild-type mice

Microglia studies (planned):

• Rapid, gentle glial isolation from brain tissue using a novel microfluidics device
• Assessment of viability, migration, cytokine and chemokine production, oxidative stress, and neuronal impact
• Comparative proteomics across paired iPSC-derived microglial lines

Biological rationale:

• Kir4.2 is an inward-rectifier potassium channel that regulates resting membrane potential and cell excitability
• Homolog Kir3.2 has been linked to neuroinflammation-mediated neurodegeneration and PD-like symptoms in Weaver mice, supporting inflammation-related roles for the Kir family

Technology readiness level

The program is at an early-to-mid discovery stage. Genetic linkage and exome sequencing data, iPSC line generation, 3D dopaminergic differentiation protocols, and initial characterization of the KCNJ15p.R28C loss-of-function variant are complete. The KCNJ15 knockout mouse has been generated and shows motor and non-motor phenotypes. Detailed mechanistic validation of Kir4.2 in neutrophil-driven inflammation and microglia-mediated neuroinflammation, along with proteomic profiling, is planned as the next phase of work. The research is currently positioned for collaborative validation and target development rather than immediate commercial deployment.